A real-world assessment of healthcare costs associated with agitation in Alzheimer’s dementia

References

• Alzheimer’s Association. 2023. Alzheimer’s disease facts and figures: Special report [cited 2023 June 16]. Available from: https://www.alz.org/media/Documents/alzheimers-facts-and-figures.pdf
   Google Scholar
• Phan SV, Osae S, Morgan JC, et al. Neuropsychiatric symptoms in dementia: considerations for pharmacotherapy in the USA. Drugs R D. 2019;19(2):93–115. doi: 10.1007/s40268-019-0272-1.
   PubMed Web of Science ®Google Scholar
• Knopman DS, Amieva H, Petersen RC, et al. Alzheimer disease. Nat Rev Dis Primers. 2021;7(1):33. doi: 10.1038/s41572-021-00269-y.
   PubMed Web of Science ®Google Scholar
• Fillit H, Aigbogun MS, Gagnon-Sanschagrin P, et al. Impact of agitation in long-term care residents with dementia in the United States. Int J Geriatr Psychiatry. 2021;36(12):1959–1969. doi: 10.1002/gps.5604.
   PubMed Web of Science ®Google Scholar
• Halpern R, Seare J, Tong J, et al. Using electronic health records to estimate the prevalence of agitation in alzheimer disease/dementia. Int J Geriatr Psychiatry. 2019;34(3):420–431. doi: 10.1002/gps.5030.
   PubMed Web of Science ®Google Scholar
• Sano M, Cummings J, Auer S, et al. Agitation in cognitive disorders: progress in the international psychogeriatric association consensus clinical and research definition. Int Psychogeriatr. 2023; 7:1–13. doi: 10.1017/S1041610222001041.
   Google Scholar
• Reus VI, Fochtmann LJ, Eyler AE, et al. The American psychiatric association practice guideline on the use of antipsychotics to treat agitation or psychosis in patients with dementia. Am J Psychiatry. 2016;173(5):543–546. doi: 10.1176/appi.ajp.2015.173501.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. FDA Approves First Drug to Treat Agitation Symptoms Associated with Dementia due to Alzheimer’s Disease 2023 [cited 2023 June 16]. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-treat-agitation-symptoms-associated-dementia-due-alzheimers-disease#:∼:text=Today%2C%20the%20U.S.%20Food%20and,treatment%20option%20for%20this%20indication.
   Google Scholar
• Magierski R, Sobow T, Schwertner E, et al. Pharmacotherapy of behavioral and psychological symptoms of dementia: state of the art and future progress. Front Pharmacol. 2020;11:1168. doi: 10.3389/fphar.2020.01168.
   PubMed Web of Science ®Google Scholar
• Porsteinsson AP, Antonsdottir IM. An update on the advancements in the treatment of agitation in alzheimer’s disease. Expert Opin Pharmacother. 2017;18(6):611–620. doi: 10.1080/14656566.2017.1307340.
   PubMed Web of Science ®Google Scholar
• Carrarini C, Russo M, Dono F, et al. Agitation and dementia: prevention and treatment strategies in acute and chronic conditions. Front Neurol. 2021;12:644317. doi: 10.3389/fneur.2021.644317.
   PubMed Web of Science ®Google Scholar
• Jones E, Aigbogun MS, Pike J, et al. Agitation in dementia: real-world impact and burden on patients and the healthcare system. J Alzheimers Dis. 2021;83(1):89–101. doi: 10.3233/JAD-210105.
   PubMed Web of Science ®Google Scholar
• Hainmueller J. Entropy balancing for causal effects: a multivariate reweighting method to produce balanced samples in observational studies. Polit Anal. 2012;20(1):25–46. doi: 10.1093/pan/mpr025.
   Web of Science ®Google Scholar
• Austin P. Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research. Communications in Statistics - Simulation and Computation. 2009;38(6):1228–1234. doi: 10.1080/03610910902859574.
   Web of Science ®Google Scholar
• Aigbogun MS, Stellhorn R, Hartry A, et al. Treatment patterns and burden of behavioral disturbances in patients with dementia in the United States: a claims database analysis. BMC Neurol. 2019;19(1):33. doi: 10.1186/s12883-019-1260-3.
   PubMedGoogle Scholar
• Cloutier M, Gauthier-Loiselle M, Gagnon-Sanschagrin P, et al. Institutionalization risk and costs associated with agitation in alzheimer’s disease. Alzheimers Dement (N Y). 2019;5(1):851–861. doi: 10.1016/j.trci.2019.10.004.
   PubMedGoogle Scholar
• Anatchkova M, Brooks A, Swett L, et al. Agitation in patients with dementia: a systematic review of epidemiology and association with severity and course. Int Psychogeriatr. 2019;31(9):1305–1318. doi: 10.1017/S1041610218001898.
   PubMed Web of Science ®Google Scholar
• Marešová P, Dolejs J, Mohelska H, et al. Cost of treatment and care for people with alzheimer’s disease: a meta- analysis. Curr Alzheimer Res. 2019;16(14):1245–1253. doi: 10.2174/1567205017666200102144640.
   PubMed Web of Science ®Google Scholar
• Kongpakwattana K, Sawangjit R, Tawankanjanachot I, et al. Pharmacological treatments for alleviating agitation in dementia: a systematic review and network meta-analysis. Br J Clin Pharmacol. 2018;84(7):1445–1456. doi: 10.1111/bcp.13604.
   PubMed Web of Science ®Google Scholar
• Mühlbauer V, Möhler R, Dichter MN, et al. Antipsychotics for agitation and psychosis in people with alzheimer’s disease and vascular dementia. Cochrane Database Syst Rev. 2021;12(12):CD013304. doi: 10.1002/14651858.CD013304.pub2.
   PubMedGoogle Scholar